Why Moderna's Stock Is Trading Higher Today

Moderna, Inc. MRNA shares are trading higher in sympathy with Pfizer and BioNTech following reports indicating the FDA is expected to fully approve Pfizer and BioNTech's COVID-19 vaccine.

Reports also suggest the FDA said Pfizer-BioNTech's COVID-19 vaccine will now be marketed as comirnaty, for prevention of COVID-19 disease in individuals 16 years of age & older.

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases.

Moderna's stock was trading about 5.5% higher at $404.01 per share Monday morning at the time of publication. The stock has a 52-week high of $497.49 and a 52-week low of $54.21.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Newswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!